- Home
- LI vs MDGL Comparison
LI vs MDGL Comparison
Compare LI & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LI | MDGL |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4B | 12.8B |
| IPO Year | 2019 | 2005 |
Fundamental Metrics
Financial Performance| Metric | LI | MDGL |
|---|---|---|
| Price | $12.34 | $507.56 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 12 |
| Target Price | $19.66 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 3.4M | 374.6K |
| Earning Date | 05-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $180,133,000.00 |
| Revenue This Year | $18.98 | $58.39 |
| Revenue Next Year | $22.72 | $48.55 |
| P/E Ratio | $29.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.65 | $351.32 |
| 52 Week High | $26.94 | $615.00 |
Technical Indicators
Market Signals| Indicator | LI | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 41.51 | 45.41 |
| Support Level | $12.06 | $503.41 |
| Resistance Level | $12.39 | $555.57 |
| Average True Range (ATR) | 0.29 | 23.89 |
| MACD | -0.05 | -0.58 |
| Stochastic Oscillator | 4.85 | 51.70 |
Price Performance
Historical ComparisonAbout LI Li Auto Inc.
Li Auto is one of China's leading new energy vehicle manufacturers. Founded in 2015, the company designs, develops, manufactures, and sells premium smart NEVs with a particular focus on family size premium SUVs and MPVs. Li Auto started volume production of its first model—the Li One, an SUV that is a premium plug-in electric vehicle- in November 2019. Besides PHEVs, its product portfolio now extends to EVs that are fully battery-powered, reaching a wide audience. It has sold over 400,000 NEVs in 2025, accounting for about 3% of China's passenger NEV market.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.